Betalipoproteins and Euglobulin Lysis Time

Summary

Previous enrichment of a plasma with betalipoproteins produce an increase of the quantity of proteins, lipids and fibrinogen precipitated with the euglobulins and a corresponding delay in the lysis time of the euglobulin clot. Unpurified betalipoproteins added to a solution of euglobulins produced a delayed lysis time of the clot obtained by coagulating the mixture with thrombin. Betalipoproteins loose their inhibitory activity when they are previously washed with distilled water; the inhibitors could be detected in the supernatant. Small amounts of the inhibitors of plasminogen activation precipitate with the euglobulins. This process is enhanced by betalipoproteins. It is supposed that the delayed lysis time of the euglobulins obtained from plasma of atherosclerotic patients is due to the increase of the fibrinogen and of the inhibitors precipitated with the euglobulins.

• References

• 1 Astrup T, Sterndorff I. Plasminogen activator in animal tissues. Acta physiol. scand 35: 250 1956;
• 2 Baciti I, Cucuianu M. Fibrinoliza în unele forme de activitate a măduvei leucopoietice. Stud. Cercet. Med 9: 319 1958;
• 3 Bang N. U, Cliffton E. F. The effect of alimentary hyperlipaemia en thrombolysis in vivo. Thrombos. Diathes. haemorrh. (Stuttg.) 4: 149 1960;
• 4 Blix S. Studies of the fibrinolytic system of the euglobulin fraction of human blood. Scand. J. clin. Lab. Invest. 13 suppl. 58 (1961).
• 5 Burstein M. Isolement des lipoprotéines sériques de faible densité après floculation par le phosphotungstate de soude a pH neutre en presence de clorure de magnésium. Nouv. Rev. franç. Hémat 3: 139 1963;
• 6 Cucuianu M. Efectul lipidelor serice asupra fibrinolizei, Stud. Cercet. Fiziol 10: 55 1965;
• 7 Donner L. Prispevak k vysetrovani fibrinolysy. Laboratorny vysetrovani, Praga 9: 816 1963;
• 8 Gajevski J. Effect of the ingestion of various fats on the fibrinolytic activity in normal subjects and in patients with coronary heart disease. J. Atheroscler. Res 1: 222 1961;
• 9 Gallimore M. J, Nulkar M. V, Shaw J. T. B. A comparative study of the inhibitors of fibrinolysis in human, dog and rabbit blood. Thrombos. Diathes. haemorrh. (Stuttg.) 14: 145 1965;
• 10 Greig H. B. W, Runde J. A. Studies of the inhibition of fibrinolysis by lipids. Lancet II: 461 1957;
• 11 Hougie C, Ayers F. Lipemia and fibrinolytic potentiality. Lancet I: 186 1960;
• 12 Howell M. A method for assessing clot lysis. J. clin. Path 17: 310 1964;
• 13 Jacobsson K. Trypsin and plasmin inhibitors in human blood serum. Scand. J. clin. Lab. Invest. 7 suppl. 14 (1955)
• 14 James D. C, Drysdale J, Billimoria J. D, Wheatley D, Gavey C, McLagan N. F. Lipemia and blood coagulation effects in relation to ischemic heart disease. Lancet II: 798 1961;
• 15 Kommerei E, Berger H. D. Untersuchungen zur Gerinnungsaktivität und Fibrinolyse bei alimentaeres Lipaemia. Klin. Wschr 37: 1029 1959;
• 16 Konttinen Y. On the effect of alimentary lipemia and a natural heparinoid on the fibrinolytic system of man. Scand. J. clin. Lab. Invest 14: 87 1962;
• 17 Kowalski E, Kopec M, Niewiarowski S. An evalution of the euglobulin method, for the determination of fibrinolysis. J. clin. Path 12: 215 1959;
• 18 Kowarzyk H, Baciu I, Oprisiu C, Kotschy M. Unele mecanisme de activare a fibrinolizei. Stud. Cercet. Med 13: 49 1962;
• 19 Merskey C, Marcus A. J. Lipids, blood coagulation and fibrinolysis. Ann. Rev. Med 14: 326 1963;
• 20 Moga A, Baciu I, Pitea P, Cucuianu M, Suciu A. Sistemul fibrinolytic sanguin in atero-scleroza umana. Stud. Cercet Med 11: 97 1960;
• 21 Moga A, Baciu I, Cucuianu M, Missits P, Suciu A, Pitea P. Sistemul fibrinolitic sanguin in ateroscleroza umana (II), Stud. Cercet. Med 14: 245 1963;
• 22 Moriau M. S, de Vries J, Dick H. J. Les inhibiteurs de la fibrinolyse et le dosage de l’activité antiplasminique physiologique et pathologique. Thrombos. Diathes. haemorrh. (Stuttg.) 20: 355 1964;
• 23 Nitzberg S. I, Peyman M, Goldstein R, Proger S. Studies of blood coagulation and fibrinolysis in patients with idiopathic hyperlipemia and primary hypercholesteremia before and after fatty meals. Circulation 19: 676 1959;
• 24 Pappenhagen A. R, Koppel J. L, Glwin J. H. Observations on the in vitro effects of chylomicrons, low-density lipoproteins and phospholipids on human plasma euglobulins lysis. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 164 1963;
• 25 Pilgeram L. O, Amundsen B. A, Lofgren P. E. Evidence for steroid control of the meth-abolism of Profibrinolysin. Thrombos. Diathes. haemorrh. (Stuttg.) 11: 94 1964;
• 26 Raynaud R, Brochier M, Griguer P. Fibrinolyse et syndrome humoral de l’athérosclérose. Presse méd 69: 2185 1961;
• 27 Raynaud R, Brochier M, Tadéi J. Action d’un héparinoïde de synthèse sur le syndrome humoral de l’athérosclérose. Arch. Mal. Coeur, Suppl. 3, Rev. Athérosclér. p. 23, (1963)
• 28 vonK aulla K. Chemistry of thrombolysis. Human fibrinolytic enzymes. Ed. Charles C. Thomas; Springfield: 1963